PDS 0204
Alternative Names: PDS-0204; SARS-CoV-2FCLatest Information Update: 28 Jul 2024
At a glance
- Originator Farmacore; PDS Biotechnology Corporation
- Class COVID-19 vaccines; Influenza virus vaccines; Protein vaccines; Recombinant fusion proteins
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported COVID 2019 infections
- Discontinued Influenza virus infections
Most Recent Events
- 28 Jul 2024 No recent reports of development identified for preclinical development in COVID-2019-infections(Prevention) in Brazil (SC, Injection)
- 28 Jul 2024 No recent reports of development identified for preclinical development in COVID-2019-infections(Prevention) in USA (SC, Injection)
- 16 Nov 2020 PDS Biotechnology has patent protection for Versamune® technology